In clinical practice, QFPDD has been shown to be effective at preventing the progression to severe COVID-19 (Ma et al., 2020; Shi et al., 2020; Jang et al., 2021), significantly improving clinical symptoms, shortening the time to a negative nucleic acid test (NAT), promoting the absorption of lung lesions, and lowering the mortality rate. The gene discussed is BRD2; the disease is COVID-19.